# ClinicalTrials.gov record NCT06606821

> PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06606821-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06606821-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06606821-tirzepatide-v1.json
- Content SHA-256: `ab328944db4d1808bf4da62c3bd8464831f844aa55bab7df711ed18c7aa5e687`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06606821 ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

## Sources

<a id="source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d"></a>
- **ClinicalTrials.gov record NCT06606821 · retained source version 2025-05-22:ce937143bf9dd9a8760a4bf86b9416b11384fdbdd8a64ddf83d37a54c7d61c7b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06606821) (`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06606821." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06606821-tirzepatide-v1.json SHA-256: ab328944db4d1808bf4da62c3bd8464831f844aa55bab7df711ed18c7aa5e687.